Cargando…
LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
BACKGROUND: SAB is common, serious, and potentially lethal. Antibiotic options are limited, especially for MRSA. Ceftobiprole is an advanced-generation cephalosporin with bactericidal activity against Gram-positive (including MRSA) and Gram-negative pathogens, with efficacy and safety demonstrated i...
Autores principales: | Holland, Thomas L, Cosgrove, Sara E, Doernberg, Sarah B, Pavlov, Oleksander, Titov, Ivan, Atanasov, Boyko, Gehr, Maziar Assadi, Engelhardt, Marc, Hamed, Kamal, Ionescu, Daniel, Jones, Mark, Sauley, Mikael, Smart, Jennifer, Seifert, Harald, Jenkins, Timothy C, Turner, Nicholas A, Fowler, Vance G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752497/ http://dx.doi.org/10.1093/ofid/ofac492.1892 |
Ejemplares similares
-
No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020) -
Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020) -
2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023) -
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
por: Overcash, J Scott, et al.
Publicado: (2020) -
Sab
por: Gómez de Avellaneda y Arteaga, Gertrudis, 1814-1873
Publicado: (1976)